Susan Margaret De Paul

USPTO Granted Patents = 9 (Patent Applications = 3)

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 9(Granted Patents)

Location History:

Zurich, CH (2011)
Zürich, CH (2012 - 2019)

Company Filing History:

5 out of 86

Lexicon Pharmaceuticals, Inc.

Years Active: 2011-2019

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10501405 - Crystalline diacylhydrazine and the use thereof (2019-12-10),

2. 9604913 - Crystalline diacylhydrazine and the use thereof (2017-03-28),

3. 9067962 - Methods of treating diabetes (2015-06-30),

4. 8946294 - Crystalline diacylhydrazine and the use thereof (2015-02-03),

5. 8735408 - Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate (2014-05-27),

6. 8653094 - Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use (2014-02-18),

7. 8217156 - Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use (2012-07-10),

8. 8193204 - Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use (2012-06-05),

9. 7884247 - Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof (2011-02-08),

Title: Susan Margaret De Paul: Innovator in Crystalline Diacylhydrazine

Introduction: Susan Margaret De Paul is a distinguished inventor based in Zurich, Switzerland. She holds an impressive portfolio with a total of nine patents to her name. Her groundbreaking work primarily revolves around the field of pharmaceuticals, particularly in the development of crystalline diacylhydrazine compounds.

Latest Patents: Among her notable contributions, her latest patents focus on crystalline polymorphic and amorphous forms of specific hydrazide compounds. These include (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 1) and (S)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 2). Her disclosures provide detailed methodologies for making and utilizing these compounds, emphasizing their applications in regulating gene expression in various biological contexts.

Career Highlights: Susan's career has been enriched by her contributions to leading companies in the pharmaceutical industry, notably Lexicon Pharmaceuticals, Inc. and Intrexon Corporation. Her expertise has led to significant advancements in the utilization of diacylhydrazine compounds in medical applications.

Collaborations: Throughout her career, Susan has collaborated with esteemed colleagues, including Anett Perlberg and Robert Eugene Hormann. These partnerships have fostered an environment conducive to innovation and research development.

Conclusion: Susan Margaret De Paul stands out as a pivotal inventor in the realm of crystalline diacylhydrazine compounds. Her achievements underscore the significance of her work in advancing pharmaceutical research, particularly in gene expression regulation. With her nine patents, she continues to inspire future innovations in the field.

This text is generated by artificial intelligence and may not be accurate.